IVD China last week: Danaher, Wantai and Hoyotek, Fosun Diagnostics and MCI, Shandong University Second Hospital and DeepSeek

Danaher Invests CNY 200 million to Expand R&D and Manufacturing Base in Shanghai

Leica Microsystems, a subsidiary of Danaher, signed an agreement to invest CNY 200 million in expanding its R&D and manufacturing base in Shanghai. In the future, 60% of Leica’s pathology business in China will be localized.

In addition, Cytiva—a Danaher life sciences pioneer—has invested nearly CNY 20 million to build a new cell culture media development base at the Cytiva China Innovation Center in Shanghai Zhangjiang. The facility will provide one-stop, customized services for Chinese biopharmaceutical companies, covering everything from early consultation, solution design, and sample preparation to post-development technical support. As another major milestone in Cytiva’s localization strategy, the new base enhances the center’s functional layout, strengthens local R&D and manufacturing capabilities, and accelerates the development of the biopharmaceutical industry in China.

Wantai Partners with Hoyotek to Advance AD Diagnostics

By the end of 2024, China’s population aged 60 and above had reached 310 million, accounting for 22% of the total population. There are nearly 10 million Alzheimer’s patients. In early 2025, China’s National Health Commission and 14 other ministries jointly issued the National Action Plan for Coping with Dementia in Older Adults (2024–2030), aiming to raise the cognitive function screening rate among the elderly to over 80% by 2030.

Hoyotek Biomedical Co., Ltd and Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. officially entered into a strategic partnership. The two parties will collaborate deeply in the field of in vitro diagnostics for brain diseases, integrating their strengths to accelerate the development of cutting-edge diagnostics for Alzheimer’s and related conditions. Together, they aim to create a full-cycle precision medical solution covering early screening, diagnosis, and monitoring, providing strong technological support in response to population aging.

Fosun Diagnostics and Oman’s MCI Form Strategic Partnership to Expand Middle East Diagnostic Market

On June 23，Fosun Diagnostics and Muscat Changming Investments LLC (MCI) officially signed a strategic cooperation framework agreement. The two parties will collaborate deeply in the areas of innovative diagnostic products, regional commercialization, and healthcare services. They aim to build a full-chain diagnostic ecosystem for the Middle East market and accelerate the accessibility of cutting-edge medical technologies in Oman and across the region, contributing to the upgrade of the local healthcare ecosystem.

Liu Yi, Chairman of Fosun Medical Devices and Diagnostics, stated: “Leveraging MCI’s strong localization capabilities, we will accelerate registration, localized manufacturing, supply chain optimization, and commercialization of these innovative products in the Middle East. We firmly believe that through the dual-channel synergy of 'bringing in' advanced technologies and 'going global' via local operations, we can achieve impactful results.”

AI-Powered Lab Medicine: DeepSeek at Shandong University Second Hospital

As China's National Health Commission’s Medical Administration Department issued a notice on piloting the management of medical laboratory physicians, placing higher demands on enhancing the clinical value of laboratories, AI is becoming a key driver in transforming the laboratory medicine discipline. In 2025, the Laboratory Medicine Center of Shandong University Second Hospital took the lead in completing the medical-grade localized deployment of DeepSeek. The center built an AI-powered system for intelligent interpretation of laboratory reports and quality management. This innovation deeply integrates large AI models into core laboratory scenarios, promoting the shift of laboratory medicine from data provision to clinical decision support.

With assistance from the Roche integrated solutions team, the Laboratory Medicine Center implemented a systematic engineering process to establish an on-premises DeepSeek + RAG intelligent analysis system. The system includes exclusive in-hospital deployment, authoritative knowledge base construction, automated report interpretation processes, and a continuously optimized intelligent engine.